Takeda’s ORZEYFUL Cleared, But Can’t Ship Yet — Asian Firms Log 32 FDA Actions This Week
Takeda’s narcolepsy drug OVEPOREXTON (ORZEYFUL) received FDA approval, but the approval letter itself says the product can’t be marketed until DEA publishes its controlled-substance scheduling notice. Meanwhile Asian companies posted 32 separate FDA approvals and clearances this week — the newsletter’s signature tracking category.
Coverage 2026-07-30 to 2026-08-05 (FDA publication basis) · Published 2026-08-11
This week’s FDA drug approvals totaled just one — Takeda’s OVEPOREXTON (ORZEYFUL) for narcolepsy type 1 — and it came with a catch: per the approval letter itself, DEA controlled-substance scheduling was not yet complete, so the legal marketing date is deferred until DEA publishes its Federal Register notice. Medical device clearances reached 79, and Asian companies (Japan, South Korea, China, Taiwan, India) accounted for 32 separate FDA actions this week, including two brand-new US market entrants.
This page is a partial excerpt from the full briefing we send to paid subscribers each week. The complete recall list, full Warning Letter detail, and the bilingual FDA approval-letter collection are member-only, as shown in the “Full Issue” section below.
THIS WEEK’S SPOTLIGHT — 4 ITEMS
Approved, but not yet marketable: ORZEYFUL’s DEA scheduling gap
Takeda’s OVEPOREXTON (ORZEYFUL) was approved 2026-08-05 for narcolepsy type 1. Per the approval letter, DEA controlled-substance scheduling was incomplete as of that date — the product cannot legally be marketed until DEA publishes its Federal Register scheduling notice, and Takeda must then file a labeling supplement.
32 Asian-company FDA actions, including 2 first-time market entrants
Samsung Electronics (South Korea), Hamamatsu Photonics and Olympus (Japan), and Taiwan Surgical Corporation all cleared devices this week. Beijing Honghugaoxiang and Resvent Medical Technology (both China) each logged their first-ever FDA clearance, marking new entrants to the US market.
“Lack of assurance of sterility” drove 4 of the week’s top 10 recalls
Rohto’s cooling eye drops, injectable pemetrexed, CLEVIPREX injectable emulsion, and BD ChloraPrep antiseptic applicators were each recalled (Class II) over sterility-assurance concerns — a notable clustering around the same root cause this week.
4 Warning Letters, 3 tied to manufacturing-quality violations
India’s Dabur India Limited and Woodbine Products Company received CGMP-related Warning Letters; Germany’s Thomas Brunner Hygiene GmbH was cited for marketing an unapproved new drug. The fourth letter concerned a US clinical investigator.
WHAT’S IN THE FULL ISSUE
510(k) / De Novo Clearances — 4 of 79 shown
| Device | Applicant | Type | Date |
|---|---|---|---|
| Sleep Apnea Feature (v2.0) | Samsung Electronics | 510(k) | 2026-07-20 |
| BubbleView Digital Flexible Cystoscope | MacroLux Medical | 510(k) | 2026-07-20 |
| Inno-Hook™ Disposable Clip Appliers | Taiwan Surgical Corp. | 510(k) | 2026-07-20 |
| OTTAVA™ Robotic Surgical System | Auris Health (J&J) | De Novo | 2026-07-21 |
- All 57 drug recalls — beyond the 4 sterility-related items shown, the remaining 53 (product, reason, class)
- Full text of all 4 Warning Letters — company, cited violation, issuing office
- FDA Official Approval Letter Collection (PDF) — this week’s ORZEYFUL approval letter in full, with strategic commentary
- Full FDA Database (Excel) — Product Code, review timelines, applicant history
ON OUR VERIFICATION PROCESS
This briefing is generated using AI, grounded strictly in FDA primary-source data (openFDA, Federal Register, and FDA.gov). To guard against the “plausible-sounding errors” generative AI can produce, we apply three layers of verification.
No claim without a source
The AI is not permitted to generate claims absent from primary-source text. Where extraction fails, the report states so explicitly rather than filling the gap.
Automated cross-check after generation
Generated text is mechanically checked against the primary source; unsupported statements are automatically flagged and removed.
Key items verified against the original letter
New drug approvals and major efficacy supplements are checked against the actual FDA approval letter before being described.